Holoxan With Uromitexan 2gm Injection

Holoxan with Uromitexan 2gm Injection is an anticancer and cytoprotective medication belonging to the class of alkylating agents and haemorrhagic cystitis inhibitors. It contains the active ingredients Ifosfamide and Mesna. These agents are indicated for treatment of bladder inflammation and cancers of soft tissue, germ cells, pancreas, and cervix. Mesna provides protection against certain adverse effects of chemotherapy medications. Do not use if there is a known allergy to this drug or any of its components. This medicine may cause severe bone marrow suppression, resulting in low white blood cell counts or low platelet counts following chemotherapy or radiation therapy. Wait three months after receiving a live virus vaccine such as measles, mumps, rubella, or chickenpox before beginning treatment with this drug. Use with caution in patients with severe kidney or liver disease. Inform your doctor of all other medications, over-the-counter medicines, or herbal products you are taking, as your doctor will evaluate potential interactions. Before using this medication, inform your doctor if you are pregnant or planning pregnancy. Holoxan with Uromitexan 2gm Injection is contraindicated in pregnancy as it may cause harm to the fetus. Your healthcare provider will perform a pregnancy test before initiating treatment. Discuss effective contraceptive methods with your doctor and use them for at least two weeks following your final dose. Breastfeeding should be avoided during treatment with this drug as it may pass into breast milk in small amounts.

Hemorrhagic cystitis (bladder inflammation) Soft tissue cancer Germ cell cancer Pancreatic cancer Cervical cancer

These two combinations together work by damaging the DNA in cancer cells, which leads to cell death and slows the growth and spread of cancer. Mostly, this involves the formation of reactive metabolites in the liver, which are then transported to cancer cells in the body. These metabolites react with the DNA in the cancer cells, causing cross-links and breaks in the DNA strands. This interferes with the replication and transcription of DNA, leading to cell death.

It will be given to you by a doctor or nurse in a hospital or clinic setting trained in cancer chemotherapy. Holoxan with uromitexan 2gm injection is given as an intravenous infusion drip (into your vein). Do not self-administer the injection. Your doctor will decide the dose and duration of the treatment based on your disease severity, body weight, and other factors.

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Serious Immune system suppression Low levels of RBC, WBC, and platelets in the blood Bone marrow suppression Nerve toxicity Urinary problems Lung problems Kidney problem Rash Hypersensitivity reactions Common Hair loss Fever Phlebitis Liver toxicity Infections

This injection may cause severe birth defects if taken during pregnancy. Female patients with reproductive potential should use effective contraception during the treatment. Male patients with female partners with reproductive potential should use effective birth control methods during the treatment and for at least 5 months after their last dose. Do not breastfeed during treatment with this injection. Your doctor may advise you to take certain tests to check for the effectiveness of the therapy. Holoxan with uromitexan 2gm injection may cause dizziness, drowsiness, or blurred vision, so it is important to avoid driving. It's important to avoid consuming grapefruit or grapefruit juice while taking this injection because this can lead to increased levels of the drug in your body and a higher risk of side effects. If you miss a dose of this drug and it is close to the time for your next scheduled dose, you should skip the missed dose and continue with your regular dosing schedule. It is not recommended to take a double dose to make up for a missed one.